mRNA 0184
Alternative Names: AZD 7970; mRNA-0184; Relaxin mRNA therapeutic - Moderna TherapeuticsLatest Information Update: 26 Apr 2024
At a glance
- Originator Moderna Therapeutics
- Class Heart failure therapies; RNA
- Mechanism of Action Relaxin expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Heart failure
Most Recent Events
- 16 Feb 2024 Phase-I clinical trials in Heart failure (In volunteers) in Australia (IV) (NCT06243770)
- 06 Feb 2024 Moderna Therapeutics plans a phase I trial in Heart failure (In volunteers) in Australia (IV, Infusion) (NCT06243770)
- 26 May 2022 Phase-I clinical trials in Heart failure in United Kingdom (IV) (ISRCTN79552451)